Table 3 Univariable and multivariable analyses for the risk factors of PGF or PT and survival post-transplantation

Patient gender

male vs. female

0.796 (0.374–1.694)

0.554

-

0.459 (0.150–1.402)

0.171

-

0.751 (0.313–1.805)

0.523

-

Patient age

< 30y vs ≥ 30y (median)

1.136 (0.534–2.416)

0.741

-

0.083 (0.0011–0.638)

*0.017

0.091 (0.012–0.708)

*0.022

0.249 (0.083–0.746)

*0.013

0.321 (0.085–1.213)

0.094

Diagnosis

AML vs. ALL

0.804 (0.378–1.711)

0.572

-

0.736 (0.247–2.190)

0.581

-

1.030 (0.427–2.486)

0.947

-

Donor age

< 45y vs ≥ 45y (median)

0.635 (0.297–1.357)

0.242

-

1.411 (0.461–4.316)

0.546

-

1.92 (0.56–6.57)

0.300

-

HLA disparity

3/6vs.4–5/6

0.661 (0.289–1.511)

0.327

-

0.545 (0.168–1.733)

0.314

-

0.985 (0.329–2.949)

0.979

-

Donor gender

male vs. female

0.732 (0.329–1.629)

0.444

-

0.431 (0.145–1.283)

0.130

0.594 (0198–1.780)

0.352

0.545 (0.222–1.334)

0.184

Relationship

Parents vs. other

1.279 (0.593–2.756)

0.530

-

0.533 (0.174–1.630)

0.270

-

0.362 (0.139–0.943)

*0.038

0.645 (0.202–2.059)

0.459

ABO blood type

other vs. major mismatch

0.679 (0.287–1.606)

0.378

0.366 (0.048–2.819)

0.335

-

0.224 (0.030–1.673)

0.145

0.205 (0.027–1.534)

0.123

CD34+ cell infused

≥ median vs.< median

0.429 (0.182–1.016)

0.054

0.400 (0.163–0.984)

*0.046

0.575 (0.177–1.868)

0.357

-

0.692 (0.276–1.735)

0.433

-

Chemo cycles before HSCT

<4 vs. ≥4 cycles

2.068 (0.905–4.724)

0.085

1.851 (0.798–4.293)

0.151

0.805 (0.270–2.399)

.696

-

1.423 (0.581–3.487)

0.440

-

Cycles to achieve CR

<2 vs. ≥2 cycles

1.014 (1.014–4.724)

0.978

0.484 (0.149–1.572)

0.227

-

0.661 (0.2401–1.821)

0.424

-

NAC prophylaxis

NAC vs. high-risk control

*0.025

0.317 (0.113–0.890)

*0.021

*0.029

0.274 (0.096–0.777)

*0.015

0.463

1.064 (0.266–4.257)

0.930

-

0.792

1.028 (0.309–3.414)

0.964

-

NAC vs. low-risk control

0.643 (0.242–1.715)

0.373

0.725 (0.270–1.945)

0.523

2.150 (0.606–7.621)

0.236

-

1.378 (0.517–3.672)

0.521

-